Skip to main content

Articles

Page 2 of 26

  1. To elucidate the clinical and ancillary features of genetic prion diseases (gPrDs) presenting with frontotemporal dementia (FTD) to aid early identification.

    Authors: Zhongyun Chen, Min Chu, Li Liu, Jing Zhang, Yu Kong, Kexin Xie, Yue Cui, Hong Ye, Junjie Li, Lin Wang and Liyong Wu
    Citation: Alzheimer's Research & Therapy 2022 14:90
  2. To promote the development of effective therapies, there is an important need to characterize the full spectrum of neuropathological changes associated with Alzheimer’s disease. In line with this need, this st...

    Authors: Dorothee Schoemaker, Maria Clara Zanon Zotin, Kewei Chen, Kay C. Igwe, Clara Vila-Castelar, Jairo Martinez, Ana Baena, Joshua T. Fox-Fuller, Francisco Lopera, Eric M. Reiman, Adam M. Brickman and Yakeel T. Quiroz
    Citation: Alzheimer's Research & Therapy 2022 14:89
  3. Inducing brain ATP-binding cassette 1 (ABCA1) activity in Alzheimer’s disease (AD) mouse models is associated with improvement in AD pathology. The purpose of this study was to investigate the effects of the A...

    Authors: Sasan D. Noveir, Bilal E. Kerman, Haotian Xian, Cristiana Meuret, Sabrina Smadi, Ashley E. Martinez, Johannes Johansson, Henrik Zetterberg, Bryan A. Parks, Zsuzsanna Kuklenyik, Wendy J. Mack, Jan O. Johansson and Hussein N. Yassine
    Citation: Alzheimer's Research & Therapy 2022 14:87
  4. Clinicians, researchers, and patients alike would greatly benefit from more accessible and inexpensive biomarkers for neural β-amyloid (Aβ). We aimed to assess the performance of fully automated plasma Aβ immu...

    Authors: Kazuto Yamashita, Masahiro Miura, Shunsuke Watanabe, Kengo Ishiki, Yuji Arimatsu, Junko Kawahira, Toshiko Kubo, Katsutaka Sasaki, Takayuki Arai, Kei Hagino, Yasuhiro Irino, Kota Nagai, David Verbel, Akihiko Koyama, Shobha Dhadda, Hayato Niiro…
    Citation: Alzheimer's Research & Therapy 2022 14:86
  5. We developed the Alzheimer’s Biomarker Survey to assess willingness to enroll in biomarker studies that disclose results and anticipated reactions to an elevated biomarker result.

    Authors: Lindsay R. Clark, Claire M. Erickson, Erin M. Jonaitis, Yue Ma, Nathaniel A. Chin, Kristin Basche, Frederick B. Ketchum and Carey E. Gleason
    Citation: Alzheimer's Research & Therapy 2022 14:85
  6. Low-intensity light can decelerate neurodegenerative disease progression and reduce amyloid β (Aβ) levels in the cortex, though the cellular and molecular mechanisms by which photobiomodulation (PBM) protects ...

    Authors: Yurii V. Stepanov, Iuliia Golovynska, Renlong Zhang, Sergii Golovynskyi, Liudmyla I. Stepanova, Oleksandr Gorbach, Taisa Dovbynchuk, Liudmyla V. Garmanchuk, Tymish Y. Ohulchanskyy and Junle Qu
    Citation: Alzheimer's Research & Therapy 2022 14:84
  7. The literature has shown depression to be associated with an increased risk of dementia. In addition, hormone therapy can be a responsive treatment option for a certain type of depression. In this study, we ex...

    Authors: Hyewon Kim, Juhwan Yoo, Kyungdo Han, Dong-Yun Lee, Maurizio Fava, David Mischoulon and Hong Jin Jeon
    Citation: Alzheimer's Research & Therapy 2022 14:83
  8. Authors: Colin Groot, Claudia Cicognola, Divya Bali, Gallen Triana-Baltzer, Jeffrey L. Dage, Michael J. Pontecorvo, Hartmuth C. Kolb, Rik Ossenkoppele, Shorena Janelidze and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2022 14:82

    The original article was published in Alzheimer's Research & Therapy 2022 14:67

  9. Authors: Miranka Wirth, Claudia Schwarz, Gloria Benson, Nora Horn, Ralph Buchert, Catharina Lange, Theresa Köbe, Stefan Hetzer, Marta Maglione, Eva Michael, Stefanie Märschenz, Knut Mai, Ute Kopp, Dietmar Schmitz, Ulrike Grittner, Stephan J. Sigrist…
    Citation: Alzheimer's Research & Therapy 2022 14:81

    The original article was published in Alzheimer's Research & Therapy 2019 11:36

  10. Validation of new biomarkers of Alzheimer disease (AD) is crucial for the successful development and implementation of treatment strategies. Additional to traditional AT(N) biomarkers, neuroinflammation biomar...

    Authors: Luka Rejc, Vanessa Gómez-Vallejo, Ana Joya, Gemma Arsequell, Ander Egimendia, Pilar Castellnou, Xabier Ríos-Anglada, Unai Cossío, Zuriñe Baz, Leyre Iglesias, Estibaliz Capetillo-Zarate, Pedro Ramos-Cabrer, Abraham Martin and Jordi Llop
    Citation: Alzheimer's Research & Therapy 2022 14:80
  11. Two main genetic risks for sporadic Alzheimer’s disease (AD) are a family history and ɛ4 allele of apolipoprotein E. The brain and retina are part of the central nervous system and share pathophysiological mec...

    Authors: Inés López-Cuenca, Alberto Marcos-Dolado, Miguel Yus-Fuertes, Elena Salobrar-García, Lorena Elvira-Hurtado, José A. Fernández-Albarral, Juan J. Salazar, Ana I. Ramírez, Lidia Sánchez-Puebla, Manuel Enrique Fuentes-Ferrer, Ana Barabash, Federico Ramírez-Toraño, Lidia Gil-Martínez, Juan Arrazola-García, Pedro Gil, Rosa de Hoz…
    Citation: Alzheimer's Research & Therapy 2022 14:79
  12. Synaptic dysfunction and degeneration are central to Alzheimer’s disease (AD) and have been found to correlate strongly with cognitive decline. Thus, studying cerebrospinal fluid (CSF) biomarkers reflecting sy...

    Authors: Johanna Nilsson, Nicholas J. Ashton, Andrea L. Benedet, Laia Montoliu-Gaya, Johan Gobom, Tharick A. Pascoal, Mira Chamoun, Erik Portelius, Andreas Jeromin, Muriel Mendes, Henrik Zetterberg, Pedro Rosa-Neto, Ann Brinkmalm and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2022 14:78
  13. Many families with clinical early-onset Alzheimer’s disease (EOAD) remain genetically unexplained. A combination of genetic factors is not standardly investigated. In addition to monogenic causes, we evaluated...

    Authors: Merel O. Mol, Sven J. van der Lee, Marc Hulsman, Yolande A. L. Pijnenburg, Phillip Scheltens, Harro Seelaar, John C. van Swieten, Laura Donker Kaat, Henne Holstege and Jeroen G. J. van Rooij
    Citation: Alzheimer's Research & Therapy 2022 14:77
  14. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13195-017-0280-8.

    Authors: Hoau-Yan Wang, Caryn Trocmé-Thibierge, Andres Stucky, Sanket M. Shah, Jessica Kvasic, Amber Khan, Philippe Morain, Isabelle Guignot, Eva Bouguen, Karine Deschet, Maria Pueyo, Elisabeth Mocaer, Pierre-Jean Ousset, Bruno Vellas and Vera Kiyasova
    Citation: Alzheimer's Research & Therapy 2022 14:76
  15. No population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and all-cause dementia and its two most common sub-types Alzheimer’s dise...

    Authors: Thi Ngoc Mai Nguyen, Li-Ju Chen, Kira Trares, Hannah Stocker, Bernd Holleczek, Konrad Beyreuther, Hermann Brenner and Ben Schöttker
    Citation: Alzheimer's Research & Therapy 2022 14:75
  16. This study sought to explore the association between Life’s Simple 7 (LS7) and cerebrospinal fluid (CSF) Alzheimer’s disease (AD) pathological biomarkers in the cognitively normal northern Chinese population.

    Authors: Yong-Li Zhao, Ya-Nan Ou, Ya-Hui Ma, Yu-Yuan Huang, Yan-Lin Bi, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2022 14:74
  17. This study assesses the relationships between dynamic functional network connectivity (DFNC) and dementia risk.

    Authors: Sophie Dautricourt, Julie Gonneaud, Brigitte Landeau, Vince D. Calhoun, Robin de Flores, Géraldine Poisnel, Salma Bougacha, Valentin Ourry, Edelweiss Touron, Elizabeth Kuhn, Harriet Demintz-King, Natalie L. Marchant, Denis Vivien, Vincent de la Sayette, Antoine Lutz and Gaël Chételat
    Citation: Alzheimer's Research & Therapy 2022 14:72
  18. Synaptic dysfunction is an early core feature of Alzheimer’s disease (AD), closely associated with cognitive symptoms. Neuregulin 1 (NRG1) is a growth and differentiation factor with a key role in the developm...

    Authors: Agathe Vrillon, François Mouton-Liger, Matthieu Martinet, Emmanuel Cognat, Claire Hourregue, Julien Dumurgier, Elodie Bouaziz-Amar, Ann Brinkmalm, Kaj Blennow, Henrik Zetterberg, Jacques Hugon and Claire Paquet
    Citation: Alzheimer's Research & Therapy 2022 14:71
  19. Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings
    Citation: Alzheimer's Research & Therapy 2022 14:70

    The original article was published in Alzheimer's Research & Therapy 2021 13:80

  20. Currently, Alzheimer’s disease (AD) cohort datasets are difficult to find and lack across-cohort interoperability, and the actual content of publicly available datasets often only becomes clear to third-party ...

    Authors: Yasamin Salimi, Daniel Domingo-Fernández, Carlos Bobis-Álvarez, Martin Hofmann-Apitius and Colin Birkenbihl
    Citation: Alzheimer's Research & Therapy 2022 14:69
  21. This work aimed to investigate the potential pathways involved in the association between social and lifestyle factors, biomarkers of Alzheimer’s disease and related dementia (ADRD), and cognition.

    Authors: Leslie Grasset, Cécile Proust-Lima, Jean-François Mangin, Marie-Odile Habert, Bruno Dubois, Claire Paquet, Olivier Hanon, Audrey Gabelle, Mathieu Ceccaldi, Cédric Annweiler, Renaud David, Therese Jonveaux, Catherine Belin, Adrien Julian, Isabelle Rouch-Leroyer, Jérémie Pariente…
    Citation: Alzheimer's Research & Therapy 2022 14:68
  22. Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals in early Alzheimer’s disease (AD) stages and for monitoring of treatment effects. Plasma measurements o...

    Authors: Colin Groot, Claudia Cicognola, Divya Bali, Gallen Triana-Baltzer, Jeffrey L. Dage, Michael J. Pontecorvo, Hartmuth C. Kolb, Rik Ossenkoppele, Shorena Janelidze and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2022 14:67

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:82

  23. Blood biomarkers that can be used for preclinical Alzheimer’s disease (AD) diagnosis would enable trial enrollment at a time when the disease is potentially reversible. Here, we investigated plasma neuronal-de...

    Authors: Tao-Ran Li, Yun-Xia Yao, Xue-Yan Jiang, Qiu-Yue Dong, Xian-Feng Yu, Ting Wang, Yan-Ning Cai and Ying Han
    Citation: Alzheimer's Research & Therapy 2022 14:66
  24. Blood phosphorylated tau (p-tau) forms are promising Alzheimer’s disease (AD) biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) plasma is limited. Firstly, we assessed th...

    Authors: Przemysław R. Kac, Fernando Gonzalez-Ortiz, Joel Simrén, Nele Dewit, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton and Thomas K. Karikari
    Citation: Alzheimer's Research & Therapy 2022 14:65
  25. The primary progressive aphasia (PPA) diagnosis trajectory is debated, as several changes in diagnosis occur during PPA course, due to phenotype evolution from isolated language alterations to global cognitive...

    Authors: A. Mouton, A. Plonka, R. Fabre, T. M. Tran, P. Robert, J. Macoir, V. Manera and A. Gros
    Citation: Alzheimer's Research & Therapy 2022 14:64
  26. The combined effects of increased life expectancy and the considerable number of persons reaching old age will magnify the dementia epidemic in the USA. Demonstration that subclinical atherosclerosis precedes ...

    Authors: Felice Lin, Judy Pa, Roksana Karim, Howard N. Hodis, S. Duke Han, Victor W. Henderson, Jan A. St. John and Wendy J. Mack
    Citation: Alzheimer's Research & Therapy 2022 14:63
  27. The entry of artificial intelligence into medicine is pending. Several methods have been used for the predictions of structured neuroimaging data, yet nobody compared them in this context.

    Authors: Leonie Lampe, Sebastian Niehaus, Hans-Jürgen Huppertz, Alberto Merola, Janis Reinelt, Karsten Mueller, Sarah Anderl-Straub, Klaus Fassbender, Klaus Fliessbach, Holger Jahn, Johannes Kornhuber, Martin Lauer, Johannes Prudlo, Anja Schneider, Matthis Synofzik, Adrian Danek…
    Citation: Alzheimer's Research & Therapy 2022 14:62
  28. Cerebrospinal fluid (CSF) lactate levels have been suggested to be associated with disease severity and progression in several neurological diseases as an indicator of impaired energy metabolism, neuronal deat...

    Authors: Paul Theo Zebhauser, Achim Berthele, Oliver Goldhardt, Janine Diehl-Schmid, Josef Priller, Marion Ortner and Timo Grimmer
    Citation: Alzheimer's Research & Therapy 2022 14:61
  29. Cerebrospinal fluid (CSF) analysis for detecting amyloid positivity may be as reliable as positron emission tomography (PET). We evaluated the performance of the amyloid beta (Aβ)42/40 ratio for predicting amy...

    Authors: Michaela Amft, Marion Ortner, Udo Eichenlaub, Oliver Goldhardt, Janine Diehl-Schmid, Dennis M. Hedderich, Igor Yakushev and Timo Grimmer
    Citation: Alzheimer's Research & Therapy 2022 14:60
  30. Slowed clearance of amyloid β (Aβ) is believed to underlie the development of Aβ plaques that characterize Alzheimer’s disease (AD). Aβ is cleared in part by the glymphatic system, a brain-wide network of peri...

    Authors: Matthew Simon, Marie Xun Wang, Ozama Ismail, Molly Braun, Abigail G. Schindler, Jesica Reemmer, Zhongya Wang, Mariya A. Haveliwala, Ryan P. O’Boyle, Warren Y. Han, Natalie Roese, Marjorie Grafe, Randall Woltjer, Detlev Boison and Jeffrey J. Iliff
    Citation: Alzheimer's Research & Therapy 2022 14:59
  31. There is currently a lack of reliable and easily accessible biomarkers predicting cognitive decline in Alzheimer’s disease (AD). Synaptic dysfunction and loss occur early in AD and synaptic loss measured in th...

    Authors: Pia Kivisäkk, Becky C. Carlyle, Thadryan Sweeney, James P. Quinn, Christopher E. Ramirez, Bianca A. Trombetta, Muriel Mendes, Mary Brock, Carrie Rubel, Julie Czerkowicz, Danielle Graham and Steven E. Arnold
    Citation: Alzheimer's Research & Therapy 2022 14:58
  32. To evaluate a wide range of optical coherence tomography (OCT) parameters for possible application as a screening tool for cognitively healthy individuals at risk of Alzheimer’s disease (AD), assessing the pot...

    Authors: Alicia López-de-Eguileta, Sara López-García, Carmen Lage, Ana Pozueta, María García-Martínez, Martha Kazimierczak, María Bravo, Juan Irure, Marcos López-Hoyos, Pedro Muñoz-Cacho, Noelia Rodríguez-Perez, Diana Tordesillas-Gutiérrez, Alexander Goikoetxea, Claudia Nebot, Eloy Rodríguez-Rodríguez, Alfonso Casado…
    Citation: Alzheimer's Research & Therapy 2022 14:57
  33. Alzheimer’s disease is the most prevalent cause of dementia in the elderly. Neuronal death and synaptic dysfunctions are considered the main hallmarks of this disease. The latter could be directly associated t...

    Authors: Andrea González, Camila Calfío, Macarena Churruca and Ricardo B. Maccioni
    Citation: Alzheimer's Research & Therapy 2022 14:56
  34. Previous models of Alzheimer’s disease (AD) progression were primarily hypothetical or based on data originating from single cohort studies. However, cohort datasets are subject to specific inclusion and exclu...

    Authors: Sepehr Golriz Khatami, Yasamin Salimi, Martin Hofmann-Apitius, Neil P. Oxtoby and Colin Birkenbihl
    Citation: Alzheimer's Research & Therapy 2022 14:55
  35. The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of dise...

    Authors: Sheila Seleri Assunção, Reisa A. Sperling, Craig Ritchie, Diana R. Kerwin, Paul S. Aisen, Claire Lansdall, Alireza Atri and Jeffrey Cummings
    Citation: Alzheimer's Research & Therapy 2022 14:54
  36. The degeneration of the cholinergic circuit from the basal forebrain to the hippocampus contributes to memory loss in patients suffering from Alzheimer’s disease (AD). However, the internal relationships betwe...

    Authors: Weilin Liu, Jianhong Li, Minguang Yang, Xiaohua Ke, Yaling Dai, Huawei Lin, Sinuo Wang, Lidian Chen and Jing Tao
    Citation: Alzheimer's Research & Therapy 2022 14:53
  37. Studies exploring topological properties of the metabolic network during the presymptomatic stage of genetic frontotemporal dementia (FTD) are scarce. However, such knowledge is important for understanding bra...

    Authors: Li Liu, Min Chu, Binbin Nie, Lin Liu, Kexin Xie, Yue Cui, Yu Kong, Zhongyun Chen, Haitian Nan, Kewei Chen, Pedro Rosa-Neto and Liyong Wu
    Citation: Alzheimer's Research & Therapy 2022 14:52
  38. Tau deposition in the mesial temporal lobe (MTL) in the absence of amyloid-β (Aβ−) occurs with aging. The tau PET tracer 18F-MK6240 has low non-specific background binding so is well suited to exploration of earl...

    Authors: Natasha Krishnadas, Vincent Doré, Colin Groot, Fiona Lamb, Pierrick Bourgeat, Samantha C. Burnham, Kun Huang, Anita M. Y. Goh, Colin L. Masters, Victor L. Villemagne and Christopher C. Rowe
    Citation: Alzheimer's Research & Therapy 2022 14:51
  39. The ability to understand emotions is often disturbed in patients with cognitive impairments. Right temporal lobe structures play a crucial role in emotional processing, especially the amygdala, temporal pole ...

    Authors: Jana Amlerova, Jan Laczó, Zuzana Nedelska, Martina Laczó, Martin Vyhnálek, Bing Zhang, Kateřina Sheardova, Francesco Angelucci, Ross Andel and Jakub Hort
    Citation: Alzheimer's Research & Therapy 2022 14:50
  40. Tau positron emission tomography (PET) is increasing in popularity for biomarker characterization of Alzheimer’s disease (AD), and recent frameworks rely on tau PET cut-points to stage individuals along the AD...

    Authors: Alexandra J. Weigand, Anne Maass, Graham L. Eglit and Mark W. Bondi
    Citation: Alzheimer's Research & Therapy 2022 14:49
  41. Neuropsychiatric symptoms (NPS) are common in individuals with Alzheimer’s disease (AD) dementia, but substantial heterogeneity exists in the manifestation of NPS. Sex differences may explain this clinical var...

    Authors: Willem S. Eikelboom, Michel Pan, Rik Ossenkoppele, Michiel Coesmans, Jennifer R. Gatchel, Zahinoor Ismail, Krista L. Lanctôt, Corinne E. Fischer, Moyra E. Mortby, Esther van den Berg and Janne M. Papma
    Citation: Alzheimer's Research & Therapy 2022 14:48
  42. Apolipoprotein E epsilon 4 (APOE-ε4) carrier status is an established risk factor for Alzheimer’s disease (AD) dementia. It has also been linked with sleep disturbance in healthy older adults and increased insomn...

    Authors: Jonathan Blackman, Seth Love, Lindsey Sinclair, Richard Cain and Elizabeth Coulthard
    Citation: Alzheimer's Research & Therapy 2022 14:47
  43. Up to now, there are no clinically available minimally invasive biomarkers to accurately identify mild cognitive impairment (MCI) patients who are at greater risk to progress to Alzheimer’s disease (AD) dement...

    Authors: Alexa Pichet Binette, Sebastian Palmqvist, Divya Bali, Gill Farrar, Christopher J. Buckley, David A. Wolk, Henrik Zetterberg, Kaj Blennow, Shorena Janelidze and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2022 14:46
  44. FACEmemory® is the first computerized, self-administered verbal episodic memory test with voice recognition. It can be conducted under minimal supervision and contains an automatic scoring system to avoid admi...

    Authors: Montserrat Alegret, Oscar Sotolongo-Grau, Ester Esteban de Antonio, Alba Pérez-Cordón, Adelina Orellana, Ana Espinosa, Silvia Gil, Daniel Jiménez, Gemma Ortega, Angela Sanabria, Natalia Roberto, Isabel Hernández, Maitee Rosende-Roca, Juan Pablo Tartari, Emilio Alarcon-Martin, Itziar de Rojas…
    Citation: Alzheimer's Research & Therapy 2022 14:43
  45. Authors: Panchanan Maiti, Zackary Bowers, Ali Bourcier-Schultz, Jarod Morse and Gary L. Dunbar
    Citation: Alzheimer's Research & Therapy 2022 14:42

    The original article was published in Alzheimer's Research & Therapy 2021 13:37

  46. Diagnostic performance of optical coherence tomography (OCT) to detect Alzheimer’s disease (AD) and mild cognitive impairment (MCI) remains limited. We assessed whether compensating the circumpapillary retinal...

    Authors: Jacqueline Chua, Chi Li, Lucius Kang Hua Ho, Damon Wong, Bingyao Tan, Xinwen Yao, Alfred Gan, Florian Schwarzhans, Gerhard Garhöfer, Chelvin C. A. Sng, Saima Hilal, Narayanaswamy Venketasubramanian, Carol Y. Cheung, Georg Fischer, Clemens Vass, Tien Yin Wong…
    Citation: Alzheimer's Research & Therapy 2022 14:41
  47. Temporary disruption of the blood-brain barrier (BBB) using pulsed ultrasound leads to the clearance of both amyloid and tau from the brain, increased neurogenesis, and mitigation of cognitive decline in pre-c...

    Authors: Stéphane Epelbaum, Ninon Burgos, Michael Canney, Dawn Matthews, Marion Houot, Mathieu D. Santin, Carole Desseaux, Guillaume Bouchoux, Sebastian Stroer, Cyril Martin, Marie-Odile Habert, Marcel Levy, Aicha Bah, Karine Martin, Benoît Delatour, Maximilien Riche…
    Citation: Alzheimer's Research & Therapy 2022 14:40